Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the next clinical milestone or spotting executive share purchases inside Neuraxis Inc’s disclosures can feel like searching for a needle in a 300-page haystack. Investors typically dive into a Neuraxis quarterly earnings report 10-Q filing for cash-burn details, or scan Neuraxis insider trading Form 4 transactions for clues ahead of pivotal trial data. That user journey starts here.
Stock Titan’s platform turns dense documents into clear insights. Our AI reads every line so you don’t have to, delivering Neuraxis SEC filings explained simply within minutes of hitting EDGAR. Need the footnotes on R&D spend? Click the AI summary under Neuraxis annual report 10-K simplified. Want alerts the second insiders move? Real-time push updates flag Neuraxis Form 4 insider transactions real-time. We also map terminology—PENFS, IB-Stim, FDA clearances—so you’re never lost while understanding Neuraxis SEC documents with AI.
Every filing type is covered in one place:
- 8-K clinical updates with Neuraxis 8-K material events explained
- Proxy materials for Neuraxis proxy statement executive compensation
- Detailed cash-flow trends via Neuraxis earnings report filing analysis
- Instant alerts on Neuraxis executive stock transactions Form 4
Whether you’re monitoring FDA timelines, gauging burn rate, or tracking insider confidence, our AI-powered summaries, expert commentary, and real-time feeds ensure you act on complete information—not on assumptions. Explore every Neuraxis disclosure the moment it lands and transform complex neuromodulation filings into actionable clarity.
NeurAxis, Inc. reported quarterly net sales of $894,086, an increase of 46.2% versus the prior-year quarter, and six‑month net sales of $1.79 million. Cash rose by $2,291,586 to $5,988,456 at June 30, 2025, driven largely by proceeds of $4,999,999 from a May 22, 2025 common stock offering (1,538,461 shares issued) and $1,002,991 from warrant exercises.
Despite revenue growth and improved liquidity, the company reported a six‑month net loss of $3,969,102 and an accumulated deficit of $60,768,714. Management and auditors disclosed substantial doubt about the company’s ability to continue as a going concern. The company accrued a $375,000 current liability and $267,540 noncurrent liability for a tentative $750,000 litigation settlement. Series B Preferred Stock outstanding totaled 3,896,907 shares and common shares outstanding were 9,858,716 as of June 30, 2025.
Neuraxis, Inc. (NRXS) Form 4 filing shows Director and 10% owner Brian P. Hannasch purchased 355,556 common shares on 07/01/2025 at $2.25 per share, an estimated cash outlay of roughly $0.8 million. The transaction was coded “P” (open-market purchase), executed directly, and lifts Hannasch’s total direct holdings to 1,131,522 shares.
Key take-aways:
- The purchase represents a sizable vote of confidence by a control insider.
- Post-transaction ownership exceeds one million shares, reinforcing alignment with minority shareholders.
- No disposals or derivative transactions were reported.
The filing contains no additional financial data or explanatory notes beyond the standard certification.
FAQ
What is the current stock price of Neuraxis (NRXS)?
What is the market cap of Neuraxis (NRXS)?
